Pfizer loses U.S. claim over co-pays for heart failure patients
A government requests court on Monday dismissed Pfizer Inc’s (PFE.N). U.S. hostile to payoff regulation that the drugmaker said kept it from aiding. Heart failure patients, numbers with low income, cost of antidote $225,000 yearly. Pfizer said making its proposed lead lawful offense would “too limit some lower-pay patients from getting to remedy they frantically … Read more